Jetra Therapeutics is a preclinical biotechnology company developing a novel engineered protein for the treatment of obesity-related liver diseases including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitus (NASH). Jetra Therapeutics is a spin-out of the University of Queensland, founded on intellectual property developed at Mater Research Institute (MRI-UQ) and licensed by UQ’s technology transfer company, UniQuest.